You are here: Industry Insights > cytokine storm

News List

Cytokine storms play a limited role in moderate-to-severe COVID-19 worldpharmanews
November 17, 2020
Rather than life-threatening hyperinflammation, most adults with moderate-to-severe COVID-19 have a suppressed viral immune response when compared to adults with another viral respiratory infection, influenza. St. Jude Children's Research Hospital and ...
Humanigen announces first patient dosed in NIH ACTIV-5/Big Effect trial evaluating lenzilumab for Covid-19 pharmaceutical-business-review
November 04, 2020
Humanigen, a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm,’ announced that the first patient has been dosed at the Emory University School of Medicine in Atlanta, Georgia as...
Researchers find corticosteroids combo is most effective for COVID-19 cytokine storm treatment expresspharma
October 22, 2020
Additionally, there was an improvement if corticosteroids were used alone, or in combination with tocilizumab or anakinra when compared with standard of care.
Potential cytokine storm treatment identified for severe COVID-19 patients europeanpharmaceuticalreview
June 09, 2020
Treating COVID-19 patients with respiratory distress with acalabrutinib, a Bruton tyrosine kinase (BTK) inhibitor reduced inflammation and improved their breathing within three days.
Clinical Ink Implements COVID-19 Therapy Trial americanpharmaceuticalreview
June 08, 2020
Clinical Ink has helped expedite the study of a treatment for cytokine storm, the immunological reaction associated with severe cases of COVID-19.
CytoAgents gets NIH funding to advance therapy for cytokine storm pharmaceutical-technology
May 15, 2020
Biotechnology company CytoAgents has received a grant from the US’ National Institutes of Health (NIH) to speed-up the development of GP1681 for the potential treatment of cytokine storm caused by Covid-19.
I-Mab to Develop TJM2 for Cytokine Release Syndrome Patients with COVID-19 americanpharmaceuticalreview
March 16, 2020
I-Mab Biopharma is initiating the development of TJM2 (TJ003234) to treat cytokine storm in severe and critically ill patients caused by the coronavirus disease (COVID-19).